GSK PLC ADR (GSK): Price and Financial Metrics

GSK PLC ADR (GSK): $36.09

0.20 (+0.56%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

B

GSK Price/Volume Stats

Current price $36.09 52-week high $39.74
Prev. close $35.89 52-week low $29.76
Day low $35.84 Volume 1,318,694
Day high $36.25 Avg. volume 3,380,429
50-day MA $35.74 Dividend yield 3.9%
200-day MA $35.44 Market Cap 73.89B

GSK Stock Price Chart Interactive Chart >

GSK POWR Grades

  • Value is the dimension where GSK ranks best; there it ranks ahead of 97.45% of US stocks.
  • GSK's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • GSK's current lowest rank is in the Momentum metric (where it is better than 9.57% of US stocks).

GSK Stock Summary

  • GSK has a market capitalization of $70,052,400,000 -- more than approximately 96.83% of US stocks.
  • With a price/earnings ratio of 3.83, GSK PLC P/E ratio is greater than that of about just 6.67% of stocks in our set with positive earnings.
  • In terms of volatility of its share price, GSK is more volatile than just 2.86% of stocks we're observing.
  • Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are STLA, GILD, CMI, NTES, and MCHP.
  • Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.

GSK PLC ADR (GSK) Company Bio


GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China ResourcesSinopharmJohnson & JohnsonPfizerRocheAbbVieNovartisBayer, and Merck. (Source:Wikipedia)


GSK Latest News Stream


Event/Time News Detail
Loading, please wait...

GSK Latest Social Stream


Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.

7 ‘Smart Money’ Stocks Set to Explode Higher

Invest like the pros by wagering on these top seven smart money stocks to buy at this time, offering tremendous upside ahead.

Muslim Farooque on InvestorPlace | September 30, 2023

Amazon Health: A long play and a search for partners

Amazon Pharmacy is just one of the segments of health that the e-retail giant is pursuing.

Yahoo | September 27, 2023

Best Dividend Stocks: British Giant GSK Offers Yield, Security For Investors

In this week's IBD Income Investor, British pharmaceutical giant GSK is in focus. Headquartered in London, GSK is a pharmaceutical company responsible for developing an abundance of drugs. In the biotech sector this yield is especially appealing considering the majority of companies do not pay a dividend at all.

Yahoo | September 27, 2023

Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

Yahoo | September 19, 2023

FDA approves GSK drug Ojjaara for myelofibrosis with anemia

More on GSK

Read More 'GSK' Stories Here

GSK Price Returns

1-mo N/A
3-mo 6.95%
6-mo N/A
1-year 22.23%
3-year 11.66%
5-year 14.97%
YTD 5.76%
2022 -16.73%
2021 26.64%
2020 -17.79%
2019 29.12%
2018 13.70%

GSK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!